Evaluation of Apoptotic Signals in Human Cancer Malignant Melanoma Me45 and Ovarian Carcinoma SKOV3 Cell Death after Chemotherapeutic Reaction with Cisplatin
Objective: The aim of this study was to evaluate the influence of chemotherapy with cisplatin (CT-cisplatin) on cell death induction in human metastatic and resistant cancer cells. Methods: There were investigated the effects of chemotherapy with cisplatin (10µM). Two lines were used: human metastatic melanoma (Me45) and human ovarian carcinoma cell line resistance to cisplatin (SKOV-3). The cytotoxic effect of cisplatin by viability assay, trypan blue, apoptotic cell death by TUNEL assay and the expression of caspase 3 and 7 by immunocytochemistry were examined. Results: Cisplatin induced decreased cellular proliferation proportionally with increasing concentration and longer incubation time. The cytotoxic effect was more significant in melanoma cells. The necrosis was observed in 3% of ovarian carcinoma cells and in 8% of malignant melanoma cells, while apoptosis was observed in 1% of ovarian carcinoma cells and in 39% of malignant melanoma cells in comparison to control untreated cells. The increased expression of caspase 3 and 7 was detected after CT-cisplatin. Conclusion: The dose of cisplatin applied in the studies was sufficient to treatment of malignant melanoma. Our studies confirmed the resistance of human ovarian carcinoma to cisplatin.
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Asia Press is a professional Science, Technology and Medicine publisher, who owns rapid publication, Peer-Reviewed, Open Access Journals. Asia Press aims to promote “knowledge sharing”. As you know, the main barrier for free “knowledge sharing” is the cost of publishing and transfer. In order to encourage scholars and scientists to the max, and devote whole power to realize the aim of “knowledge sharing” and the benefit of “all” mankind, Asia Press performs a permanent policy of no charge for publication and access, and always open its door for authors worldwide.